ABVX Trading Analysis - 10/23/2026 12:44 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge of Abivax SA (ABVX) and are separated from the data-driven analysis below:

• Abivax reported updated Phase 3 trial results for obefazimod in ulcerative colitis, with regulatory submission preparation ongoing in the EU and US (mid-2026).
• Company completed a secondary equity financing in Q3 2026 to extend cash runway past pivotal readouts.
• Biotech sector saw broad volatility as FDA advisory panel schedules stirred speculation on oral IBD drug classes.
• No confirmed near-term earnings date; fiscal year end per fundamentals is 2025-12-01 with trailing EPS of -5.85 indicating pre-revenue stage.
• Headlines suggest speculative catalyst risk; this contrasts with embedded technicals showing a downtrend and options sentiment showing bullish directional conviction.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data for ABVX:

• Trailing EPS is -5.85; company is loss-making with no trailing PE, forward PE, or PEG ratio available (all null).
• Revenue growth, gross/operating/net margins, ROE, debt-to-equity, and free cash flow are not provided (null).
• Market cap is $7,832,662,000.00 with 87,272,000.00 shares outstanding and institutional ownership at 12.91%.
• Dividend yield is 0.00%; no dividend rate or ex-dividend date.
• 52-week range: $69.81 low to $148.83 high; current price $89.75 is in lower third of annual range.
• Historical volatility is 53.85%; average volume 1,316,000.00; beta not provided.
• Analyst consensus, target mean price, and number of opinions are null — no street view embedded.
• Fundamentals show a pre-revenue biotech with heavy losses; this diverges from bullish options sentiment but aligns with weak technical trend (price below SMAs).

Current Market Position

Current price per indicators is $89.75 (daily close 2026-10-22 $89.75). Recent daily action: from 2026-09-11 close $118.64 to 2026-10-22 close $89.75, a decline of ~24.4%. Last 5 minute bars (2026-10-22 15:35–15:55) show recovery from $89.65 to $90.23 with volume 81,835 total in final 5 bars, indicating late-session intraday uplift.

Minute bars show open 2026-10-21 at $93.86, high $96.39, then fade to $89.75 by 2026-10-22; intraday momentum turned positive only in final 20 minutes.

Technical Analysis

Price $89.75 is below SMA 5 ($90.18), SMA 20 ($91.03), and SMA 50 ($103.93) — bearish alignment, no golden cross. RSI 45.08 shows neutral-to-weak momentum. MACD -4.05 below signal -3.24 with negative histogram -0.81 confirms bearish pressure. Bollinger mid $91.03, price beneath; lower band $83.21, upper $98.85 — no squeeze, mild expansion. 30-day range high $119.02, low $84.11; price near 30% of range, closer to low.

True Sentiment Analysis (Delta 40-60 Options)

Per embedded options sentiment file:

Call Volume: $256,170.00 (88.6%) Put Volume: $32,855.00 (11.4%) Total: $289,025.00

• Sentiment flagged Bullish with 289 call contracts vs 61 put contracts.
• Pure directional conviction (Delta 40-60) shows strong call lean — 7 call trades, 13 put trades but larger call notional.
• Near-term expectation: directional players positioning for upside despite bearish technicals.
• Divergence: options bullish, technicals bearish (confirmed by spread recommendation "Divergence detected").

Key Price Levels (Observational Only)